http://www.companiesandmarkets.com/
The ADHD market is currently valued at $3.85 billion and is set to increase over the next 10 years at a CAGR of 1.2%. Despite the continuing dominance of stimulant drugs, the 2002 launch of Strattera, the first non-stimulant treatment for ADHD, and the 2006 launch of Daytrana have served to open up the market, giving
patients and physicians a greater choice of treatment options.
Scope
Sales volume and value forecasts to 2017 of marketed brands, generics, and key late-stage pipeline drugs.
Analysis of patient potential, unmet needs and clinical trial design in the ADHD market.
Overview of key marketed brands and late stage pipeline drugs.
Identification of future market events that are expected to affect ADHD revenues.
Highlights
Estimated to be twice the size of the pediatric ADHD population, the highly prevalent, yet largely untapped, adult ADHD population continues to represent an attractive niche to target. The rising awareness of ADHD brought about by marketing campaigns for Adderall XR and Strattera has paved the way for the entry of additional adult ADHD drugs.
Due to a lack of innovation, none of the forecast drugs have the potential to match the commercial success experienced by currently marketed brands. Shire''s Intuniv (guanfacine)
J&J''s Concerta''s strong uptake is due to its first-to-market status as a once-daily ADHD treatment. Anticipated approval for use in adult patients, combined with Adderall XR''s patent expiry will see Concerta becoming the market leader by 2017. However, owing to patent litigations, the timing of Concerta''s genericization remains uncertain.
Reasons to Purchase
Benchmark key late-stage pipeline ADHD drugs against current market leading brands.
Assess region-specific (US, Japan, 5EU) sales forecasts of key late-stage pipeline drugs and marketed brands.
Understand unmet needs and opportunities in the ADHD market based on key opinion leader comments.
http://www.companiesandmarkets.com/
